Oncolytics Biotech is trading at $0.72, up 5.08% on September 28, 2026; no clearly documented catalyst for the intraday gain surfaced in available search results. - The latest identified company news was positive preclinical research announced September 10; no direct causal link to the gain is established. - Broader markets are lower amid rising oil prices, Treasury yields, and geopolitical concerns, a backdrop that does not explain the stock’s move higher.